Adaptyv Biosystems

Adaptyv Biosystems

AI-driven protein design and synthesis platform

Overview

Adaptyv Biosystems designs and sells custom proteins—such as antibodies and enzymes—produced using AI-guided design and cell-free synthetic biology. Its process uses automated workcells to express and test thousands of protein designs on demand, with experimental data feeding back into AI models to improve future designs. A forthcoming AI-enabled foundry will integrate sequencing design, experimental planning, autonomous execution, and data tracking across the protein-engineering cycle. The company aims to shorten development timelines and deliver protein designs that can prevent or treat disease, differentiating itself through end-to-end automation, cell-free expression, and iterative AI optimization.

YC Company

About Adaptyv Biosystems

Simplify's Rating
Why Adaptyv Biosystems is rated
C+
Rated C on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Robotics & Automation

AI & Machine Learning

Biotechnology

Healthcare

Company Size

11-50

Company Stage

Series A

Total Funding

$8.5M

Headquarters

Lausanne, Switzerland

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Over 30 companies, including pharmas, adopted platform post-$8M seed launch.
  • Y Combinator and ACE Ventures funding expands team and infrastructure rapidly.
  • Nipah virus competition tests 1,000 designs, boosting data and visibility.

What critics are saying

  • AlphaFold 3 commoditizes validation, slashing experiment demand in 6-12 months.
  • Ginkgo Bioworks outcompetes with larger funding and pharma ties immediately.
  • Pharma like Genentech builds internal foundries, capturing margins in 12 months.

What makes Adaptyv Biosystems unique

  • Adaptyv Bio automates design-test-learn cycle with AI and cell-free synthetic biology.
  • Cloud lab validates AI protein designs in 3 weeks using nanofluidic workcells.
  • Proteinbase shares 1,000+ proteins' experimental data openly for reproducibility.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$8.5M

Below

Industry Average

Funded Over

5 Rounds

Notable Investors:
Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Below Average

Industry standards

$15M
$5.9M
Adaptyv Biosystems
$8.2M
Discord
$15M
Canva
$30M
Kalshi

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-6%

2 year growth

-6%
Startupticker.ch
Dec 26th, 2025
CHF 100'000 for Adaptyv Bio and Hexem

Adaptyv Bio: an easier way to engineer proteins using an automated cloud labEpalinges-based Adaptyv Bio has taken protein engineering to a whole new level. Acting as a high-tech protein foundry, the start-up speeds up the design process for proteins. As of today, protein engineering remains a long, very tedious, and expensive task as labs and companies lack the automation and data integration to perform repeatable, scalable protein testing. This is where Adaptyv Bio works its magic: taking advantage of its automated wet lab the company builds a solution for rapid experimental validation of newly designed proteins, while also drastically reducing the costs per protein.
Combined with artificial intelligence, this new technology will make it easier for protein designers to engineer new proteins for a variety of applications, such as designed antibodies, novel enzymes or alternative materials.The Tech Seed loan from FIT will enable Adaptyv to verify the commercial validity of its antibody screening platform and roll out access to the platform at the end of this year.Hexem produces biogas from wastewater cleaningHexem has developed a novel wastewater technology, which produces biogas from industrial waste streams. Its technology uses electrical currents in a bioreactor to clean up contaminated water and produce biogas out of it.
 Nowadays, cleaning industrial wastewater costs enormous amounts of money. Yet, wastewater is an untapped resource containing nutrients and energy alike. Full energy recovery would make wastewater treatment not only energy-neutral but also profitable. And that’s what Hexem enables.The startup’s main users are in the food and beverage industry such as dairies, breweries, wineries and other producers of high strength wastewater like biofuel refineries. With Hexem’s bioreactor installed, they will be able to significantly reduce their water treatment cost and produce clean energy, which can then be reused directly.In the upcoming months, Hexem will build an industrial demonstrator in its container workshop in Port-Valais, thanks to the FIT Tech Seed loan. After ensuring the technical feasibility, this demonstrator will be transferred to an industrial site in Valais.(Press release)

Greater Geneva Bern area (GGBa)
Oct 27th, 2025
Adaptyv Biosystems raises $8M for AI lab

Adaptyv Biosystems, a Vaud-based start-up, has raised $8 million in seed funding to enhance its automated cloud lab for AI-powered protein validation. The funding round was led by ACE Ventures with participation from ByFounders, Founderful, LongGame Ventures, and individual investors. Adaptyv's platform automates the "design–test–learn" cycle, allowing researchers to validate AI-generated protein designs remotely, speeding up the experimental validation process.

BioAlps Association
Sep 26th, 2025
Adaptyv Raises CHF 6,40 million to Accelerate AI-Driven Protein Validation

Vaud-based startup Adaptyv, specializing in the experimental validation of ai-generated proteins, has raised CHF 6,40 million in seed funding.

Startupticker.ch
Sep 19th, 2025
Adaptyv Bio Exits Beta, Raises $8M

Adaptyv Bio has officially launched its protein design platform after leaving the beta phase, following an $8 million seed round led by Ace Ventures. The platform, which uses AI to facilitate rapid protein testing and synthesis, has been adopted by over 30 companies, including major pharma firms and AI labs. The funding will help Adaptyv expand its team and infrastructure to meet growing demand.

Startupticker.ch
Apr 17th, 2023
Adaptyv Bio Launches Its Protein-Engineering Platform

EPFL Spinoff Adaptyv Bio is dedicated to closing the loop between computational prediction and experimental validation with cell-free synthetic biology and high-throughput nanofluidics. Its protein engineering platform is now available in the market.Identifying new antibodies is fundamental in fighting diseases such as viral infections, autoimmune diseases, and cancers. Unfortunately, the current process for testing the efficacy of new antibodies is slow and expensive and has a failure rate of around 88%. Combining robotics, microfluidics and synthetic biology techniques, Adaptyv Bio is building a full-stack platform – protein foundry – that allows protein engineers to design and test new proteins and generate data about their proteins in order to develop new medicines, better enzymes for research and industrial applications or functional materials with novel properties. To enable that tight feedback loop from computational design to experimental validation, Adaptyv is innovating on all levels of the technology stack: from custom synthetic biology techniques for designing DNA, synthesizing proteins and assaying them, to novel lab-on-chip modular work cells that can replace multiple commercial instruments at once, to advanced lab robotics that allow the company to run experiments autonomously. This will reduce reagent consumption, time per experiment and thus cost per data point generated by multiple orders of magnitude compared to today’s approaches

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Adaptyv Biosystems right now.

Find jobs on Simplify and start your career today

We update Adaptyv Biosystems's jobs every few hours, so check again soon! Browse all jobs →